Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P46952
UPID:
3HAO_HUMAN
Alternative names:
3-hydroxyanthranilate oxygenase; 3-hydroxyanthranilic acid dioxygenase
Alternative UPACC:
P46952; A6NE56; B4DIN2; Q53QZ7; Q8N6N9
Background:
3-Hydroxyanthranilate 3,4-dioxygenase, also known as 3-hydroxyanthranilate oxygenase or 3-hydroxyanthranilic acid dioxygenase, plays a crucial role in the kynurenine pathway of tryptophan degradation. This enzyme catalyzes the oxidative ring opening of 3-hydroxyanthranilate to 2-amino-3-carboxymuconate semialdehyde, a precursor to quinolinate, an important compound in NAD+ biosynthesis.
Therapeutic significance:
The enzyme's association with Vertebral, cardiac, renal, and limb defects syndrome 1, a congenital malformation syndrome, underscores its potential as a target for therapeutic intervention. Understanding the role of 3-hydroxyanthranilate 3,4-dioxygenase could open doors to potential therapeutic strategies.